Search research articles
Contact Us
Filters
Showing results (81-90 of 93) with videos related to
Page
of 10
Sort By:
Cellular Signalling
|
August 23, 2011
A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination
Vaibhav Kapuria, Alexander Levitzki, William G Bornmann, et al.
Transplantation
|
November 27, 2002
Inhibition of aortic allograft vasculopathy by local delivery of platelet-derived growth factor receptor tyrosine-kinase blocker AG-1295
Matthias Karck, Rolf Meliss, Michael Hestermann, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 13, 2017
PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice
Yael Langut, Alaa Talhami, Samarasimhareddy Mamidi, et al.
Bioorganic & Medicinal Chemistry
|
April 3, 2003
Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit
Aviv Gazit, Kevin Yee, Andrea Uecker, et al.
Cardiovascular Research
|
September 15, 2004
Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries
Shmuel Banai, S David Gertz, Lilach Gavish, et al.
Journal of Medicinal Chemistry
|
June 10, 2011
Backbone cyclic peptide inhibitors of protein kinase B (PKB/Akt)
Yftah Tal-Gan, Mattan Hurevich, Shoshana Klein, et al.
Plos One
|
May 5, 2026
EGFR-targeted affibody-polyIC polyplex kills EGFR-overexpressing cancer cells without activating the EGFR
Anne Pettikiriarachchi, Yelena Ugolev, Richard Birkinshaw, et al.
Cancer Immunology Research
|
June 1, 2016
HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment
Maya Zigler, Alexei Shir, Salim Joubran, et al.
Cancer Biology & Therapy
|
January 17, 2004
The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation
Hong He, Yumiko Hirokawa, Aviv Gazit, et al.
Molecular Cancer Therapeutics
|
December 17, 2002
Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone
Lyudmila Burdelya, Robyn Catlett-Falcone, Alexander Levitzki, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 93) with videos related to
Sort By:
Page
of 10
Cellular Signalling
|
August 23, 2011
A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination
Vaibhav Kapuria, Alexander Levitzki, William G Bornmann, et al.
Transplantation
|
November 27, 2002
Inhibition of aortic allograft vasculopathy by local delivery of platelet-derived growth factor receptor tyrosine-kinase blocker AG-1295
Matthias Karck, Rolf Meliss, Michael Hestermann, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 13, 2017
PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice
Yael Langut, Alaa Talhami, Samarasimhareddy Mamidi, et al.
Bioorganic & Medicinal Chemistry
|
April 3, 2003
Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit
Aviv Gazit, Kevin Yee, Andrea Uecker, et al.
Cardiovascular Research
|
September 15, 2004
Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries
Shmuel Banai, S David Gertz, Lilach Gavish, et al.
Journal of Medicinal Chemistry
|
June 10, 2011
Backbone cyclic peptide inhibitors of protein kinase B (PKB/Akt)
Yftah Tal-Gan, Mattan Hurevich, Shoshana Klein, et al.
Plos One
|
May 5, 2026
EGFR-targeted affibody-polyIC polyplex kills EGFR-overexpressing cancer cells without activating the EGFR
Anne Pettikiriarachchi, Yelena Ugolev, Richard Birkinshaw, et al.
Cancer Immunology Research
|
June 1, 2016
HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment
Maya Zigler, Alexei Shir, Salim Joubran, et al.
Cancer Biology & Therapy
|
January 17, 2004
The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation
Hong He, Yumiko Hirokawa, Aviv Gazit, et al.
Molecular Cancer Therapeutics
|
December 17, 2002
Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone
Lyudmila Burdelya, Robyn Catlett-Falcone, Alexander Levitzki, et al.
Page
of 10